Friday, December 7, 2018
Rockville biotech firm stock drops despite positive drug trial results
But industry analysts declared the drug was still not superior enough to the two generics on the market to differentiate itself, and shares in Supernus fell almost 16% yesterday. The company says it remains optimistic that the small number of treatment options available still gives their product a niche in the market. “We believe these data from the two pivotal Phase III studies, which are consistent with the Phase IIb data, demonstrate that SPN-812 is a well-differentiated novel non-stimulant treatment option for many children with ADHD," Supernus CEO Jack Khattar said Thursday.